Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer
详细信息 查看全文
- 作者：Charlene Portera ; charlene.porter@nhs.net" class="auth_mail" title="E-mail the corresponding author ; Sylvia Armstrong-Fisherb ; c ; sylvia.armstrong-fisher@nhs.net" class="auth_mail" title="E-mail the corresponding author ; Tim Kopotshad ; Tim.Kopotsha@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Bryan Smithd ; Bryan.Smith@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Terry Bakerd ; Terry.Baker@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Lara Kevorkiand ; Lara.Kevorkian@ucb.com" class="auth_mail" title="E-mail the corresponding author ; Andrew Nesbittd ; Andrew.Nesbitt@ucb.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：Anti-TNF ; Certolizumab pegol ; Fc receptor ; Immunoglobulin transport ; Materno-fetal transfer
- 刊名：Journal of Reproductive Immunology
- 出版年：2016
- 出版时间：August 2016
- 年：2016
- 卷：116
- 期：Complete
- 页码：7-12
- 全文大小：1007 K
文摘
- •
FcRn plays a key role in active antibody transfer from mother to fetus.
- •
There was no measurable affinity of anti-TNF CZP binding to human FcRn.
- •
Human FcRn-mediated CZP transcytosis was less than the negative-control antibody.
- •
CZP transport was below detection in 5 of 6 human placentas perfused ex vivo.
- •
Our results support the hypothesis that CZP structure limits its transfer through the placenta to the fetus.